Skip to main content
< Back to news
Gate2Brain's team and integrants from Shilpa Pharma Lifesciences in their headquarters in Karnataka. Photo / Gate2Brain
 20.05.2025

Gate2Brain receives over €700,000 from the CDTI to advance a new therapy against pediatric brain tumors in collaboration with India

The biotech company Gate2Brain, located in the Barcelona Science Park, has been awarded funding from CDTI Innovación under the Multipaís 2024 program, a key milestone to advance its drug delivery platform for the central nervous system (CNS). In this context, Spain and India will collaborate to accelerate the preclinical and clinical development of G2B-002, a new therapy for high-grade pediatric brain tumors. This funding will support the completion of regulatory preclinical studies and will drive the start of clinical trials in early 2028.

The spinoff from IRB Barcelona, the University of Barcelona (UB), and the Sant Joan de Déu Hospital in Barcelona has secured over €700,000 in funding from CDTI Innovación, marking an important step forward for Gate2Brain, which strengthens its innovative approach to drug delivery for central nervous system diseases.

This funding is part of Spain’s Recovery, Transformation, and Resilience Plan, within the framework of the PERTE Vanguard Health initiative, which supports the development of pioneering health technologies with the potential to transform patient care. The project is also backed by the Ministry of Science and Innovation and the European Union (NextGenerationEU), reflecting the strategic importance of this research.

An international collaboration for a high-impact therapy

With the support of the CDTI Multipaís program, Gate2Brain is driving an international initiative involving Gate2Brain and the Indian company Shilpa Pharma Lifesciences to accelerate the clinical development of G2B-002. This patented peptide transport technology is specifically designed for the treatment of high-grade pediatric brain tumors and has already demonstrated effective penetration of the blood-brain barrier, promising anticancer activity in preclinical models, and good tolerance in early studies, laying the foundation for its clinical validation.

This funding will allow Gate2Brain to finalize the regulatory preclinical development of G2B-002 and advance towards a clinical trial in pediatric patients with diffuse midline glioma (DMG) by the end of 2027.

Transforming pediatric oncology and CNS drug delivery

Gate2Brain ’s groundbreaking peptide-based platform represents a paradigm shift in non-invasive and efficient drug transport across the blood–brain barrier, a major challenge in CNS drug development. While the initial focus is on pediatric brain tumors, this technology holds significant potential for broader applications in the treatment of other CNS diseases.

» Link to the news: Gate2Brain [+]